Bayer : Not intended for U.S. and UK Media -- New Real-World Evidence on Venous and Arterial Blood Clot Management including Bayer’s Xarelto® Accepted for Presentation at ESC Congress 2016 -- New real-world data will provide further insights on the use of Xarelto across diverse patient populations seen in everyday clinical practice / Results from the real-world observational XAPASS study of Xarelto in everyday patients with non-valvular AF in Japan will be presented during a Late-Breaking Registri

News Release

Bayer AG Communications, Government Relations & Corporate Brand

51368 Leverkusen Germany

Tel. +49 214 30-0

www.news.bayer.com

• New real-world data will provide further insights on the use of Xarelto across diverse patient populations seen in everyday clinical practice

• Results from the real-world observational XAPASS study of Xarelto in everyday patients with non-valvular AF in Japan will be presented during a Late-Breaking Registries Session

• New real-world data from REVISIT-US investigating rivaroxaban, apixaban and dabigatran, each compared with warfarin, in patients with non-valvular AF will be presented during a Poster Session

  Berlin, August 22, 2016 - Bayer AG announced today that new clinical and real-world data on its oral Factor Xa inhibitor Xarelto®(rivaroxaban) will be presented at ESC Congress 2016, to be held from August 27 to 31 in Rome, Italy. Notably, a total of 20 late- breaking, oral and poster presentations will feature real-world studies, highlighting the increasing significance of real-world evidence. This is important as it better represents the diverse patient populations treated in everyday clinical practice, providing insights

  complementary to the Phase III clinical trials.

  Note: Per ESC Embargo Policy, all below mentioned abstracts are under embargo until the start of the ESC Press Conference or scientific presentation, whichever comes first.

  Real-World Evidence in the Routine Management of Blood Clots Provides Additional Insights Beyond the Randomised Clinical Trials

  The real-world observational XAPASS study investigating the safety and effectiveness of rivaroxaban in patients with non-valvular atrial fibrillation (AF) in Japan will be presented as part of a Late-Breaking Registry Session:

  • XAPASS: Evidence of Safety and Effectiveness in Japanese Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation under Real-World Clinical Practice

    • Oral Session: Registries atrial fibrillation

    • Monday 29 August, 09:15-09:30, Raphael - The Hub

      A further 13 oral and poster presentations will provide new real-world insights on venous and arterial blood clot management:

      In patients with atrial fibrillation:

  • Major bleeding among patients with atrial fibrillation treated with rivaroxaban or warfarin in Sweden. Interim results from an on-going post-authorization study

    • Oral Session: Are you still afraid about bleeding risk of antithrombotic therapy in atrial fibrillation?

    • Sunday 28 August, 14:54-15:12, Minsk - Village 4

  • The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts decline in renal function over time in patients with atrial fibrillation and chronic kidney disease

    • Rapid Fire Abstract: Clinical features and management of atrial fibrillation

    • Monday 29 August, 09:33-09:42, Agora 1 - Poster Area

  • Real-world evidence of stroke prevention in patients with non-valvular atrial fibrillation in the United States: the REVISIT-US study

    • Poster Session 3: Anticoagulation in atrial fibrillation II

    • Sunday 28 August, 14:00-18:00, Poster Area

  • Real-world evidence of stroke prevention in patients with non-valvular atrial fibrillation

    • Poster Session 3: Anticoagulation in atrial fibrillation II

    • Sunday 28 August, 14:00-18:00, Poster Area

  • Economic Evaluation of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain

    • Poster Session 3: Stroke and more

    • Sunday 28 August, 14:00-18:00, Poster Area

  • Predictors of major bleeding in patients with atrial fibrillation treated with rivaroxaban in XANTUS: findings from a real-world prospective study

    • Poster Session 3: Anticoagulation in atrial fibrillation III

    • Sunday 28 August, 14:00-18:00, Poster Area

  • Oral anticoagulant prescribing patterns for stroke prevention in atrial fibrillation among general practitioners and cardiologists in three European countries

    • Poster Session 3: Anticoagulation in atrial fibrillation III

    • Sunday 28 August, 14:00-18:00, Poster Area

      In patients with a pulmonary embolism and / or deep vein thrombosis:

  • Is Rivaroxaban Associated with Shorter Hospital Stays and Reduced Costs vs. Parenteral Bridging to Warfarin Among Pulmonary Embolism Patients?

    • Oral Session: Optimizing the treatment of pulmonary embolism

    • Sunday 28 August, 17:24-17:42, Vienne - Village 9

  • Subgroup analysis of patients with concomitant pulmonary embolism in XALIA, a non-interventional study of rivaroxaban in routine treatment of deep vein thrombosis

    • Moderated Poster Session: Advances in pulmonary embolism

    • Monday 29 August, 15:35-15:42, Moderated Poster Station, Poster Area

  • Risk of Venous Thromboembolism Recurrences in Patients who Continued versus Discontinued Rivaroxaban Therapy After an Initial Six-month Therapy

    • Rapid Fire Abstract: Antithrombotics in daily clinical practice

    • Tuesday 30 August, 16:39-16:48, Galileo - The Hub

  • Outcomes Associated with Observation Versus Inpatient Stays for Pulmonary Embolism

    • Poster Session 4: Acute pulmonary embolism

    • Monday 29 August, 08:30-12:30, Poster Area

  • Hospitalizations and Other Healthcare Resource Utilization among Patients with Deep Vein Thrombosis Treated with Rivaroxaban versus Low-Molecular-Weight Heparin and Warfarin in the Outpatient Setting

    • Poster Session 4: Thrombosis and coagulation

    • Monday 29 August, 08:30-12:30, Poster Area

  • External Validation of a Multivariable Claims-Based Prediction Rule for In-Hospital Pulmonary Embolism Mortality

    • Poster Session 4: Acute pulmonary embolism

    • Monday 29 August, 08:30-12:30, Poster Area

      Additionally, six presentations from the independent GARFIELD-AF (Global Anticoagulant Registry in the FIELD) and ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registries will provide new real-world insights on diagnosis and treatment patterns in patients with non-valvular AF:

  • Identifying patients with atrial fibrillation and "truly low" thromboembolic risk who are poorly characterized by CHA2DS2-VASc: Superior performance of a novel machine learning tool in GARFIELD-AF

    • Late-Breaking Oral Session: Registries atrial fibrillation

    • Monday 29 August, 08:30-08:45, Raphael - The Hub

  • Association of Inappropriate Dosing of Non-Vitamin K Oral Anticoagulants and Risk of Adverse Events: Results from the ORBIT-AF II Registry

    • Late-Breaking Oral Session: Registries atrial fibrillation

    • Monday 29 August, 09:30-09:45, Raphael - The Hub

  • Patterns of Amiodarone Use and Outcomes in Clinical Practice for Atrial Fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)

    • Poster Session 4: Miscellaneous in arrhythmia

    • Monday 29 August, 08:30-12:30, Poster Area

  • Pharmacotherapy for atrial fibrillation in patients with chronic kidney disease: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)

    • Poster Session 4: Miscellaneous in arrhythmia

    • Monday 29 August, 08:30-12:30, Poster Area

  • Do baseline characteristics account for geographical variations in event rates in patients with newly diagnosed atrial fibrillation? The GARFIELD-AF registry

    • Moderated Poster Session: Antithrombotic therapy in atrial fibrillation 1

    • Monday 29 August, 15:56-16:03, Moderated Poster Station, Poster Area

  • Vitamin K antagonist control for patients with nonvalvular atrial fibrillation in Eastern and Southeastern Asia: An analysis of event rates from GARFIELD-AF

    • Moderated Poster Session: Antithrombotic therapy in atrial fibrillation 2

    • Tuesday 30 August, 10:35-10:45, Moderated Poster Station, Poster Area